ITPI20090151A1 - Estensione degli usi specifici della deina, di cui al brevetto d'invenzione pct/ib 2008 002562 "derivati dell'idrocortisone e loro usi per indicazioni terapeutiche o cosmetiche" - Google Patents
Estensione degli usi specifici della deina, di cui al brevetto d'invenzione pct/ib 2008 002562 "derivati dell'idrocortisone e loro usi per indicazioni terapeutiche o cosmetiche" Download PDFInfo
- Publication number
- ITPI20090151A1 ITPI20090151A1 IT000151A ITPI20090151A ITPI20090151A1 IT PI20090151 A1 ITPI20090151 A1 IT PI20090151A1 IT 000151 A IT000151 A IT 000151A IT PI20090151 A ITPI20090151 A IT PI20090151A IT PI20090151 A1 ITPI20090151 A1 IT PI20090151A1
- Authority
- IT
- Italy
- Prior art keywords
- diseases
- states
- deina
- painful
- nervous system
- Prior art date
Links
- JYGXADMDTFJGBT-VWUMJDOOSA-N Hydrocortisone Natural products O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 title 1
- 239000002537 cosmetic Substances 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
- 201000010099 disease Diseases 0.000 claims description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 9
- 230000001354 painful effect Effects 0.000 claims description 9
- 206010028980 Neoplasm Diseases 0.000 claims description 6
- 210000002435 tendon Anatomy 0.000 claims description 5
- 201000004384 Alopecia Diseases 0.000 claims description 4
- 206010019233 Headaches Diseases 0.000 claims description 4
- 208000019695 Migraine disease Diseases 0.000 claims description 4
- 231100000869 headache Toxicity 0.000 claims description 4
- 238000002636 symptomatic treatment Methods 0.000 claims description 4
- 206010027476 Metastases Diseases 0.000 claims description 3
- 208000010668 atopic eczema Diseases 0.000 claims description 3
- 210000003169 central nervous system Anatomy 0.000 claims description 3
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 3
- 210000004872 soft tissue Anatomy 0.000 claims description 3
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 2
- 208000027932 Collagen disease Diseases 0.000 claims description 2
- 208000018522 Gastrointestinal disease Diseases 0.000 claims description 2
- 208000002720 Malnutrition Diseases 0.000 claims description 2
- 208000007101 Muscle Cramp Diseases 0.000 claims description 2
- 208000025747 Rheumatic disease Diseases 0.000 claims description 2
- 208000005392 Spasm Diseases 0.000 claims description 2
- 208000017515 adrenocortical insufficiency Diseases 0.000 claims description 2
- 230000032683 aging Effects 0.000 claims description 2
- 230000000172 allergic effect Effects 0.000 claims description 2
- 230000015572 biosynthetic process Effects 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims description 2
- 210000005226 corpus cavernosum Anatomy 0.000 claims description 2
- 238000005755 formation reaction Methods 0.000 claims description 2
- 208000014951 hematologic disease Diseases 0.000 claims description 2
- 230000001071 malnutrition Effects 0.000 claims description 2
- 235000000824 malnutrition Nutrition 0.000 claims description 2
- 230000002503 metabolic effect Effects 0.000 claims description 2
- 210000000653 nervous system Anatomy 0.000 claims description 2
- 239000003176 neuroleptic agent Substances 0.000 claims description 2
- 230000000701 neuroleptic effect Effects 0.000 claims description 2
- 201000001119 neuropathy Diseases 0.000 claims description 2
- 230000007823 neuropathy Effects 0.000 claims description 2
- 208000015380 nutritional deficiency disease Diseases 0.000 claims description 2
- 210000002345 respiratory system Anatomy 0.000 claims description 2
- 208000013363 skeletal muscle disease Diseases 0.000 claims description 2
- 210000003699 striated muscle Anatomy 0.000 claims description 2
- 201000006489 suppurative thyroiditis Diseases 0.000 claims description 2
- 208000019553 vascular disease Diseases 0.000 claims description 2
- 238000011374 additional therapy Methods 0.000 claims 1
- 210000004709 eyebrow Anatomy 0.000 claims 1
- 210000000720 eyelash Anatomy 0.000 claims 1
- 210000004209 hair Anatomy 0.000 claims 1
- 230000007420 reactivation Effects 0.000 claims 1
- 208000004434 Calcinosis Diseases 0.000 description 5
- 230000001154 acute effect Effects 0.000 description 5
- 230000002308 calcification Effects 0.000 description 5
- 201000008482 osteoarthritis Diseases 0.000 description 5
- 208000002193 Pain Diseases 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 230000036407 pain Effects 0.000 description 4
- 206010010071 Coma Diseases 0.000 description 3
- 201000004624 Dermatitis Diseases 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000000642 iatrogenic effect Effects 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 208000004998 Abdominal Pain Diseases 0.000 description 2
- 206010057645 Chronic Inflammatory Demyelinating Polyradiculoneuropathy Diseases 0.000 description 2
- 208000030939 Chronic inflammatory demyelinating polyneuropathy Diseases 0.000 description 2
- 208000002881 Colic Diseases 0.000 description 2
- 206010010741 Conjunctivitis Diseases 0.000 description 2
- 208000011231 Crohn disease Diseases 0.000 description 2
- 206010011732 Cyst Diseases 0.000 description 2
- 201000011275 Epicondylitis Diseases 0.000 description 2
- 206010037549 Purpura Diseases 0.000 description 2
- 241001672981 Purpura Species 0.000 description 2
- 208000008765 Sciatica Diseases 0.000 description 2
- 208000004760 Tenosynovitis Diseases 0.000 description 2
- 231100000360 alopecia Toxicity 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 208000031513 cyst Diseases 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 206010065579 multifocal motor neuropathy Diseases 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- 230000001148 spastic effect Effects 0.000 description 2
- 230000003319 supportive effect Effects 0.000 description 2
- 201000004595 synovitis Diseases 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 206010066728 Acute interstitial pneumonitis Diseases 0.000 description 1
- 208000003130 Alcoholic Neuropathy Diseases 0.000 description 1
- 206010002965 Aplasia pure red cell Diseases 0.000 description 1
- 200000000007 Arterial disease Diseases 0.000 description 1
- 206010003422 Articular calcification Diseases 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 206010004485 Berylliosis Diseases 0.000 description 1
- 206010048962 Brain oedema Diseases 0.000 description 1
- 208000009079 Bronchial Spasm Diseases 0.000 description 1
- 208000014181 Bronchial disease Diseases 0.000 description 1
- 206010006482 Bronchospasm Diseases 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 description 1
- 208000023355 Chronic beryllium disease Diseases 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 208000019399 Colonic disease Diseases 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- 206010011844 Dacryocystitis Diseases 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- 206010012455 Dermatitis exfoliative Diseases 0.000 description 1
- 206010013700 Drug hypersensitivity Diseases 0.000 description 1
- 208000001708 Dupuytren contracture Diseases 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 208000027776 Extrapyramidal disease Diseases 0.000 description 1
- 208000001640 Fibromyalgia Diseases 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 206010017711 Gangrene Diseases 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 206010018634 Gouty Arthritis Diseases 0.000 description 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 description 1
- 208000031071 Hamman-Rich Syndrome Diseases 0.000 description 1
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 1
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 description 1
- 208000018650 Intervertebral disc disease Diseases 0.000 description 1
- 206010022941 Iridocyclitis Diseases 0.000 description 1
- 208000003456 Juvenile Arthritis Diseases 0.000 description 1
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 1
- 206010024612 Lipoma Diseases 0.000 description 1
- 201000009324 Loeffler syndrome Diseases 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- 206010026865 Mass Diseases 0.000 description 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 206010050819 Musculoskeletal chest pain Diseases 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 201000002481 Myositis Diseases 0.000 description 1
- 206010029240 Neuritis Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 206010034010 Parkinsonism Diseases 0.000 description 1
- 208000020758 Peyronie disease Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 206010035669 Pneumonia aspiration Diseases 0.000 description 1
- 206010036774 Proctitis Diseases 0.000 description 1
- 206010036783 Proctitis ulcerative Diseases 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Substances CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 206010037423 Pulmonary oedema Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010037779 Radiculopathy Diseases 0.000 description 1
- 208000012322 Raynaud phenomenon Diseases 0.000 description 1
- 206010038910 Retinitis Diseases 0.000 description 1
- 241000842539 Rhagades Species 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 206010039094 Rhinitis perennial Diseases 0.000 description 1
- 206010039705 Scleritis Diseases 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 description 1
- 206010040849 Skin fissures Diseases 0.000 description 1
- 208000010040 Sprains and Strains Diseases 0.000 description 1
- 208000000491 Tendinopathy Diseases 0.000 description 1
- 206010043255 Tendonitis Diseases 0.000 description 1
- 206010048873 Traumatic arthritis Diseases 0.000 description 1
- 206010045171 Tumour pain Diseases 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 206010046851 Uveitis Diseases 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 201000004073 acute interstitial pneumonia Diseases 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000009285 allergic inflammation Effects 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 208000004631 alopecia areata Diseases 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 201000004612 anterior uveitis Diseases 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 201000009807 aspiration pneumonia Diseases 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 description 1
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 1
- 208000010217 blepharitis Diseases 0.000 description 1
- 201000005668 blepharoconjunctivitis Diseases 0.000 description 1
- 208000006752 brain edema Diseases 0.000 description 1
- 230000001612 cachectic effect Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 208000019069 chronic childhood arthritis Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 208000006111 contracture Diseases 0.000 description 1
- 208000012208 de Quervain disease Diseases 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 208000024732 dysthymic disease Diseases 0.000 description 1
- 230000002497 edematous effect Effects 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 230000000925 erythroid effect Effects 0.000 description 1
- 208000004526 exfoliative dermatitis Diseases 0.000 description 1
- 208000024386 fungal infectious disease Diseases 0.000 description 1
- 229940084434 fungoid Drugs 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 208000013397 idiopathic acute eosinophilic pneumonia Diseases 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 230000003601 intercostal effect Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000035987 intoxication Effects 0.000 description 1
- 231100000566 intoxication Toxicity 0.000 description 1
- 201000004614 iritis Diseases 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 description 1
- 206010023332 keratitis Diseases 0.000 description 1
- 201000010666 keratoconjunctivitis Diseases 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 201000006938 muscular dystrophy Diseases 0.000 description 1
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 238000002638 palliative care Methods 0.000 description 1
- 201000011264 priapism Diseases 0.000 description 1
- 201000005825 prostate adenocarcinoma Diseases 0.000 description 1
- 208000005333 pulmonary edema Diseases 0.000 description 1
- 201000009732 pulmonary eosinophilia Diseases 0.000 description 1
- 206010061928 radiculitis Diseases 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 208000004124 rheumatic heart disease Diseases 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- 210000003786 sclera Anatomy 0.000 description 1
- 208000008742 seborrheic dermatitis Diseases 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 208000023924 subacute bursitis Diseases 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 201000004415 tendinitis Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 230000002568 urticarial effect Effects 0.000 description 1
- 210000001745 uvea Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000001457 vasomotor Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/191—Carboxylic acids, e.g. valproic acid having two or more hydroxy groups, e.g. gluconic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Rheumatology (AREA)
- Birds (AREA)
- Emergency Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Otolaryngology (AREA)
- Reproductive Health (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Ophthalmology & Optometry (AREA)
- Vascular Medicine (AREA)
Description
DESCRIZIONE
seguito degli esiti positivi, riscontrati con ulteriori tests, qui di seguito descriviamo gli ulteriori usi specifici della molecola planare dal peso molecolare di 382Dalton, il cui nome IUPAC corrisponde a\3-[3,5- Dihydroxy-3-(2-hydrìxy-acetyl)-3a,6-dimethyl-7 -oxo-dodecahydro-cyclopenta [a]naphthalen-6-yl]-propionic acid e indicata con il nome di fantasia DEINA®, ad estensione c/ell' International application number PCT/IB 5 2008/002562 .(International publication number W02009/044251)
-Somministrazione diretta intra-articolare, intraborsale, nelle guaine tendinee e nelle formazioni cistiche tendinee comprese quelle calcifiche. Sinovite da osteoartrosi, Artrite reumatoide, Artrite traumatica, Borsite acuta e subacuta, Epicondilite. Fibromiosite. Tenosinoviti, Malattia di Dupuytren, Osteoartrosi post-traumatica, Calcificazioni intrarticolari, Calcificazioni intraguainali, Calcificazioni periarticolari, Dito a scatto. Cisti tendinee. Cisti di Beker, Tunnel carpale, Tendiniti.Peritendiniti, Malattie di De Quervain, Lipomi
-Iniezioni nei tessuti molli
Nevrite intercostale. Calcificazioni dei tessuti mollLNevralgie. Ischialgia.Radicoliti.Polineuriti diabetiche. Polineuriti alcoliche arteriopatie obliteranti degli arti con dolore ischemico o da gangrenaSpondilite cervicale. Dolore in sede lombare. Trattamento locale di contusioni, distorsioni, mialgie, strappi, lombaggine, sciatica, fìbrosite, dolori intercostali.
- Iniezioni nelle neoplasie primarie e nelle metastasi
Iniezioni nelle metastasi osseelniezioni nell ’adenocarcinoma della prostata Iniezioni diretta nelle neoplasie. Dolori carnate da diversa origine e stadio evolutivo(mieloma multiplo, ed altre emopatie dolorose
-Spasmi della muscolatura striata di varia natura
Da accessi febbrli in età pediatrica anche di vecchia durata. Da post- coma. Da malattie degenerative delSistema nervoso centrale (Parkinson, Sclerosi multipla, ecc.). Sindromi extrapiramidali. Contratture spastiche e dolorose della muscolatura scheletrica. Miodistrofia.
-Malattie degenerative del Sistema nervoso
Sierosi Laterale Amiotrofica. Sierosi multipla (trattamento di supporto) Malattia e sindrome di Parkinson (trattamento di supporto). Sindrome di Guillain-Barré. Miastenia Gravis.Stato comatoso e coma CIDP(Poliradicoloneuropatia cronica infiammatoria demielinizzante . (MMN)Neuropatia motoria multifocale '
Malattie vascolari del Sistema nervoso centrale
-Neuropatie iatrogene e metaboliche
- Trattamento sintomatico delle affezioni dolorose muscolo scheletrico
-Psicostimolante, inootropo e neurolettico
Distimia.Sindrome da stanchezza cronicaSindrome psico-organica.
-Cefalee ed Emicranie
Cefalee congestizie accessionali. Emicranie tipiche. Emicranie da cefalee vasomotorie
-Insufficienza corticosurrenale
-Shock (come terapia supplementare)
-Trattamento sintomatico di stati dolorosi
Statti dolorosi post-operatori e post traumatici.Artrosi cervicali.Discopatie intervertebrali.Traum scheletrici. Dolori tumorali.Coliche renali.Coliche epatiche
-Tiroidite non suppurativa
- Malattie reumatiche
Osteoartrosi post-traumatiche. Sinovite da osteoartrosi.Artrite reumatoide.Borsite acuta e suba Epicondilite. Tensosinovite acuta aspecifica. Artrite gottosa acuta. Artrite psorioasica .Spondili anchilosante. Artrite reumatoide giovanile. Artrite reumatoide.
-Malattie del Collagene
Lupus eritematoso sistemico. Sclerodermia
-Malattie Dermatologiche
Pemfigoragadi. Sindrome di Stevens Johnson. Dermatiti. Dermatite esfoliativa.Dermatite bollosa erpetiforme. Dermatite seborroica.Micosi fungoide. Psoriasi. Acne vulgaris da lieve a moderata, specialmente in presenza di reazioni e lesioni infiammatorie.
-Stati Allergici
Stati asmatici. Asma bronchiale. Dermatiti da contatto. Dermatite atopica. Rinite allergica.Rinite perenneReazioni di ipersensibilità ai farmaciReazioni orticariodi iatrogene
-Oftalmologia
Processi infiammatori specifici e aspecifici e allergici dell ’ occhio e suoi annessi. Uveiti. Retiniti Calcificazioni della sclera.Congiuntiviti. Cheratocongiuntiviti. Blefariti. Dacriocistiti.
Blefarocongiuntiviti. Episcieriti. Scleriti. Reazioni post-operatorie. Stati infiammatori anche associati a stati dolorosi e non su basi infettiva, a carico del segmento anteriore dell ’ occhio .
Infiammazioni dell ’ uvea anteriore (iriti, iridocicliti, scleriti, episcieriti e miositi, cataratta.
-Malattie gastrointestinali
Colite ulcerosa. Morbo di Crohn.Colon irritabile.Flogosi idiopatiche intestinali acute e croniche a localizzazione anorettale e perianale.Manifestazioni spastico-dolorose del tratto gastroenterico. Enterite regionale.Ragadi anali.ColiteColonpatie funzionali. Proctiti ulcerose.Sintomi e complicanze delle emorroidi (Ragadi, prurito, bruciore , eczemi ed eritemi)
-Malattie dell’apparato respiratorio
SarcoidosiSindrome di LoefflerBerilliosi. Polmonite da aspirazione. Enfisema polmonare complicato da broncospasmoEdemi polmonariSindrome di Hamman-Rich
-Malattie ematologiche e cardiovascolari
Anemia emolitica autoimmune. Porpora trombocitopenia idiopatica.Porpora trombocitopenia secondaria.Eritroblastopenia.Anemia eritroide. Morbo di BugerMorbo e fenomeno di Raynaud. Cardite reumatica
-Stati cachettici (invecchiamento, neoplasia, denutrizione ecc.)
-Malattìe Neoplastiche
Coadiuvante dei trattamenti palliativi antìneoplatiche
-Stati edematosi
Edema cerebrale di varia eziologia (tumori primari, metastatici e recidive , accidentivascolari, chirurgia, traumi, pseudo tumori,
-Malattie dei Corpi cavernosi
Calcificazione dei corpi cavernosi.Fibrosi dei corpi cavernosi.Priapismo
-Alopecia
Alopecia areata universale. Alopecia da cause iatrogene di varia natura (chemioterapici, metalli pesanti, intossicazioni, sostanze ormonali, ecc.). Alopecia di natura ignota.
Claims (1)
- RIVENDICAZIONI ULTERIORI USI DELLA DEINA® 1 )-Somministrazione diretta intra-articolare, intraborsale, nelle guaine tendinee e nelle formazioni cistiche tendinee comprese quelle calcifiche. 2)-lniezioni nei tessuti molli. 3)-lniezioni nelle neoplasie primarie e nelle metastasi. 4)-Spasmi della muscolatura striata di varia natura. 5)-Malattie degenerative del sistema nervoso. 6) -Malattie vascolari del sistema nervoso centrale. 7)-Neuropatie iatrogene e metaboliche. 8)-Trattamento sintomatico delle affezioni dolorose muscolo scheletrico. 9)-Psicostimolante, inootropo e neurolettico. 10)-Cefalee ed emicranie. 11) -Insufficienza corticosurrenale. 12)-Shock (come terapia supplementare). 13)-Trattamento sintomatico di stati dolorosi. 14) -Tiroidite non suppurativa. 15) -Malattie reumatiche. 16)-Malattie del collageno. 17)-Malattie dermatologiche. 18)-Stati allergici. 19)-Oftalmogia. 20) -Malattie gastrointestinali. 21)-Malattie dell'apparato respiratorio. 22) -Malattie ematologiche e cardiovascolari. 23) -Stati cachettici (invecchiamento , neoplasia, denutrizione ecc.). 24) -Malattie neoplastiche 25) -Stati edematosi. 26) -Malattie dei corpi cavernosi. 27) -Alopecia. (Riattivazione del pollico pilifero delle sopracciglia e ciglia.
Priority Applications (10)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT000151A ITPI20090151A1 (it) | 2009-11-27 | 2009-11-27 | Estensione degli usi specifici della deina, di cui al brevetto d'invenzione pct/ib 2008 002562 "derivati dell'idrocortisone e loro usi per indicazioni terapeutiche o cosmetiche" |
| RU2012126664/15A RU2567041C2 (ru) | 2009-11-27 | 2010-11-26 | ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ И ТЕРАПЕВТИЧЕСКОЕ ПРИМЕНЕНИЕ ПРОИЗВОДНОГО ГИДРОКОРТИЗОНА, ОБОЗНАЧЕННОГО КАК Deina |
| CN2010800538334A CN102858331A (zh) | 2009-11-27 | 2010-11-26 | 称为deina的氢化可的松衍生物的药物组合物和治疗应用 |
| BR112012012607A BR112012012607A2 (pt) | 2009-11-27 | 2010-11-26 | composições farmacêuticas e aplicações terapêuticas de um derivado de hidrocortisona designado como deina |
| PL10809043T PL2504004T3 (pl) | 2009-11-27 | 2010-11-26 | Kompozycje farmaceutyczne i zastosowania terapeutyczne pochodnej hydrokortyzonu o nazwie deina |
| EP10809043.2A EP2504004B1 (en) | 2009-11-27 | 2010-11-26 | Pharmaceutical compositions and therapeutic applications of a hydrocortisone derivative designated as deina |
| ES10809043.2T ES2542629T3 (es) | 2009-11-27 | 2010-11-26 | Composiciones farmacéuticas y aplicaciones terapéuticas de un derivado de hidrocortisona designado como Deina |
| PCT/IB2010/055455 WO2011064753A1 (en) | 2009-11-27 | 2010-11-26 | Pharmaceutical compositions and therapeutic applications of a hydrocortisone derivative designated as deina |
| US13/511,968 US8680326B2 (en) | 2009-11-27 | 2010-11-26 | Pharmaceutical compositions and therapeutic applications of a hydrocortisone derivative designated as deina |
| ZA2012/03658A ZA201203658B (en) | 2009-11-27 | 2012-05-18 | Pharmaceutical compositions and therapeutic applications of a hydrocortisone derivatives designated as deina |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT000151A ITPI20090151A1 (it) | 2009-11-27 | 2009-11-27 | Estensione degli usi specifici della deina, di cui al brevetto d'invenzione pct/ib 2008 002562 "derivati dell'idrocortisone e loro usi per indicazioni terapeutiche o cosmetiche" |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ITPI20090151A1 true ITPI20090151A1 (it) | 2011-05-28 |
Family
ID=43640227
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IT000151A ITPI20090151A1 (it) | 2009-11-27 | 2009-11-27 | Estensione degli usi specifici della deina, di cui al brevetto d'invenzione pct/ib 2008 002562 "derivati dell'idrocortisone e loro usi per indicazioni terapeutiche o cosmetiche" |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US8680326B2 (it) |
| EP (1) | EP2504004B1 (it) |
| CN (1) | CN102858331A (it) |
| BR (1) | BR112012012607A2 (it) |
| ES (1) | ES2542629T3 (it) |
| IT (1) | ITPI20090151A1 (it) |
| PL (1) | PL2504004T3 (it) |
| RU (1) | RU2567041C2 (it) |
| WO (1) | WO2011064753A1 (it) |
| ZA (1) | ZA201203658B (it) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106540314B (zh) * | 2016-11-25 | 2019-10-08 | 陕西巨子生物技术有限公司 | 一种类人胶原蛋白鼻腔粘膜修复凝胶 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB864710A (en) * | 1956-12-24 | 1961-04-06 | Upjohn Co | Improvements in or relating to therapeutic compositions and the manufacture thereof |
| US2951074A (en) * | 1958-04-30 | 1960-08-30 | Merck & Co Inc | C14 cortical steroids and methods of preparing same |
| US5929111A (en) * | 1996-12-18 | 1999-07-27 | Alcon Laboratories, Inc. | A-seco steroids effective at treating ophthalmic pathological neovascularization and controlling intraocular pressure |
| EP1619200A1 (en) | 2004-07-05 | 2006-01-25 | Lonza Ag | Process for the preparation of 4-azasteroids |
| WO2006051287A1 (en) | 2004-11-10 | 2006-05-18 | Arrow International Limited | Composition and method for treatment of alopecia areata |
| US7964582B2 (en) * | 2005-03-21 | 2011-06-21 | J&J Consumer Companies, Inc. | Methods of treating skin and mucosal tissue atrophy using compositions including tensioning polymers |
| RU2304429C2 (ru) * | 2005-04-29 | 2007-08-20 | Тамази Владимирович Баззаев | Мазь для лечения дегенеративно-дистрофических заболеваний опорно-двигательной системы |
| ITMI20071905A1 (it) | 2007-10-04 | 2009-04-05 | Tender Aps | Derivati dell'idrocortisone e loro uso per indicazioni terapeutiche o cosmetiche |
-
2009
- 2009-11-27 IT IT000151A patent/ITPI20090151A1/it unknown
-
2010
- 2010-11-26 EP EP10809043.2A patent/EP2504004B1/en active Active
- 2010-11-26 US US13/511,968 patent/US8680326B2/en not_active Expired - Fee Related
- 2010-11-26 CN CN2010800538334A patent/CN102858331A/zh active Pending
- 2010-11-26 BR BR112012012607A patent/BR112012012607A2/pt not_active Application Discontinuation
- 2010-11-26 WO PCT/IB2010/055455 patent/WO2011064753A1/en not_active Ceased
- 2010-11-26 RU RU2012126664/15A patent/RU2567041C2/ru active
- 2010-11-26 PL PL10809043T patent/PL2504004T3/pl unknown
- 2010-11-26 ES ES10809043.2T patent/ES2542629T3/es active Active
-
2012
- 2012-05-18 ZA ZA2012/03658A patent/ZA201203658B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2504004B1 (en) | 2015-04-15 |
| RU2567041C2 (ru) | 2015-10-27 |
| US8680326B2 (en) | 2014-03-25 |
| CN102858331A (zh) | 2013-01-02 |
| WO2011064753A1 (en) | 2011-06-03 |
| US20120283327A1 (en) | 2012-11-08 |
| PL2504004T3 (pl) | 2015-09-30 |
| RU2012126664A (ru) | 2014-01-20 |
| ZA201203658B (en) | 2013-08-28 |
| BR112012012607A2 (pt) | 2016-07-12 |
| ES2542629T3 (es) | 2015-08-07 |
| EP2504004A1 (en) | 2012-10-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ahmed et al. | Novel piperazine–chalcone hybrids and related pyrazoline analogues targeting VEGFR-2 kinase; design, synthesis, molecular docking studies, and anticancer evaluation | |
| Zhu et al. | Cocrystals of baicalein with higher solubility and enhanced bioavailability | |
| Zhang et al. | Synthesis, molecular modeling and biological evaluation of N-benzylidene-2-((5-(pyridin-4-yl)-1, 3, 4-oxadiazol-2-yl) thio) acetohydrazide derivatives as potential anticancer agents | |
| JP6730321B2 (ja) | メニンとｍｌｌタンパク質との相互作用を阻害する方法及び組成物 | |
| Bayomi et al. | Synthesis and biological evaluation of new curcumin analogues as antioxidant and antitumor agents: molecular modeling study | |
| Ikeda et al. | Structure–activity relationship in the antitumor activity of 6-, 8-or 6, 8-substituted 3-benzylamino-β-carboline derivatives | |
| Zhang et al. | Biocompatible G-Quadruplex/BODIPY assembly for cancer cell imaging and the attenuation of mitochondria | |
| JP2019501904A (ja) | Ｄｎａメチルトランスフェラーゼの阻害剤としての２，４，６，７−四置換キノリン化合物 | |
| Jin et al. | Ethyl 2-(benzylidene)-7-methyl-3-oxo-2, 3-dihydro-5H-thiazolo [3, 2-a] pyrimidine-6-carboxylate analogues as a new scaffold for protein kinase casein kinase 2 inhibitor | |
| Sukhorukov et al. | Synthesis and characterization of novel 1, 2-oxazine-based small molecules that targets acetylcholinesterase | |
| CN107698657A (zh) | 基于vhl配体和bet抑制剂诱导bet降解的双功能分子及其制备和应用 | |
| Sur et al. | Naphthalenediimide-linked bisbenzimidazole derivatives as telomeric G-quadruplex-stabilizing ligands with improved anticancer activity | |
| ITPI20090151A1 (it) | Estensione degli usi specifici della deina, di cui al brevetto d'invenzione pct/ib 2008 002562 "derivati dell'idrocortisone e loro usi per indicazioni terapeutiche o cosmetiche" | |
| Lee et al. | Design, synthesis and biological evaluation of novel imidazopyridines as potential antidiabetic GSK3β inhibitors | |
| Jo et al. | The synthesis and anticancer activities of chiral epoxy-substituted chromone analogs | |
| Liu et al. | Structure-based design, synthesis and biological evaluation of diphenylmethylamine derivatives as novel Akt1 inhibitors | |
| CN108794473B (zh) | 一种苝酰亚胺-野尻毒素衍生物及其制备方法与应用 | |
| Santos et al. | Overview of the new bioactive heterocycles as targeting topoisomerase inhibitors useful against colon cancer | |
| El-Wakil et al. | Identification of new 5-(2, 6-dichlorophenyl)-3-oxo-2, 3-dihydro-5H-thiazolo [3, 2-a] pyrimidine-7-carboxylic acids as p38α MAPK inhibitors: design, synthesis, antitumor evaluation, molecular docking and in silico studies | |
| Kabir et al. | Novel anthraquinone derivatives as dual inhibitors of topoisomerase 2 and casein kinase 2: in silico studies, synthesis and biological evaluation on leukemic cell lines | |
| Ogunlakin et al. | Design, synthesis, and characterization of cinnamic acid derivatives with two novel acrylohydrazones on HeLa and CHO-1 cancer cell lines: the experimental and computational perspective | |
| Tang et al. | Decoding the epitranscriptome: a new frontier for cancer therapy and drug resistance | |
| Wei et al. | Design, synthesis, and biological evaluation of benzenesulfonyl chloride-substituted evodiamine derivatives as potential PGAM1 inhibitors | |
| Binjawhar et al. | In vitro anti-breast cancer study of hybrid cinnamic acid derivatives bearing 2-thiohydantoin moiety | |
| Kumar et al. | Influence of linker length in shape recognition of B∗ DNA by dimeric aminoglycosides |